Improved oral bioavailability of fexofenadine hydrochloride using lipid surfactants: Ex vivo, in situ and in vivo studies

Drug Development and Industrial Pharmacy

Volumn 40, Issue 8, 2014, Pages 1030-1043

  Eedara, Basanth Babu ^a   Veerareddy, Prabhakar Reddy ^a   Jukanti, Raju ^a   Bandari, Suresh ^a  

^a ST PETER'S INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Bioavailability; Dissolution; Fexofenadine hydrochloride; Gelucire 44 14; Permeation; Vitamin E TPGS

Indexed keywords

EMULSIFYING AGENT; FEXOFENADINE; GELUCIRE; MULTIDRUG RESISTANCE PROTEIN; TOCOFERSOLAN; WATER; ALPHA TOCOPHEROL; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; DRUG CARRIER; GELUCIRE 44-14; LIPID; MACROGOL DERIVATIVE; SURFACTANT; TERFENADINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; INTESTINAL GUT SAC TECHNIQUE; INTESTINE MUCOSA PERMEABILITY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PROCEDURES; RAT; SCANNING ELECTRON MICROSCOPY; SOLID STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; CHEMISTRY; INTESTINE ABSORPTION; ORAL DRUG ADMINISTRATION; PERMEABILITY; SOLUBILITY; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG CARRIERS; INTESTINAL ABSORPTION; LIPIDS; MALE; PERMEABILITY; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE-ACTIVE AGENTS; TERFENADINE; VITAMIN E;

EID: 84905507269     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.801984     Document Type: Article

References (35)

1. Qi S, Yulian L, Takahiro H, et al. Modulation of intestinal Pglycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 2006; 313:49-56.
2. Hunter J, Hirst HB. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 1997;25:129-57.
3. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301-21.
4. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71: 11-20.
5. Drescher S, Schaeffeler E, Hitzl M, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-34.
6. Meret MF, Jurgen B, Reinhard D, et al. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. Br J Clin Pharmacol 2002;53:576-81.
7. Manthena VSV, Ramesh P. Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J Pharm Sci 2005;94:1694-704.
8. Bhagwant DR, Joseph PYK, James EP. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Biopharm 2002;16:237-46.
9. Hugger ED, Novak BL, Burton PS, et al. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002; 91:1991-2002.
10. Shono Y, Nishihara H, Matsuda Y, et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci 2004;93:877-85.
11. Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, pluronic P85 and vitamin E d-alphatocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte based metabolism in excised rat intestine. AAPS PharmSci 2002;4:193-205.
12. Yu-li L. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J Control Release 2003;90:37-48.
13. Chambin O, Jannin V. Interest of multifunctional lipid excipients: case of Gelucire 44/14. Drug Dev Ind Pharm 2005;31: 527-34.
14. Rahman MA, Hussain A, Hussain MS, et al. Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS). Drug Dev Ind Pharm 2013;39: 1-19.
15. Kristina SB, Andrea T, Stephen DL, Kishor MW. Lipid excipients peceol and gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within caco-2 cells. J Pharm Pharmaceut Sci 2007;10: 319-31.
16. Dintaman JM, Silverman JA. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999;16:1550-6.
17. Takatsune Y, Ippei K, Keiichi Y, et al. Aminoalkyl methacrylate copolymers for improving the solubility of tacrolimus. I: evaluation of solid dispersion formulations. Int J Pharm 2012;428:18-24.
18. Higuchi J, Connors K. Phase solubility techniques. Adv Anal Chem Instrum 1965;4:117-212.
19. De Waard H, Hinrichs WLJ, Visser MR, et al. Unexpected differences in dissolution behavior of tablets prepared from solid dispersions with a surfactant physically mixed or incorporated. Int J Pharm 2008;349:66-73.
20. Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol 1975;27:48-9.
21. Al-Hamidia H, Edwardsa AA, Mohammad MA, Nokhodchi A. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations. Colloids Surf B: Biointerfaces 2010;76:170-8.
22. Valleri M, Mura P, Maeshrelli F, et al. Development and evaluation of glyburide fast dissolving tablets using solid dispersion technique. Drug Dev Ind Pharm 2004;30:525-34.
23. Nai-Ning S, Quan-Sheng L, Chang-Xiao L. Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol 2006;12:4064-70.
24. Sinko PJ, Hu P, Waclawski AP, Patel NR. Oral absorption of anti- AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations. J Pharm Sci 1995;84:959-65.
25. Svensson US, Sandstrom R, Carlborg O, et al. High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement. Drug Metab Dispos 1999;27:227-32.
26. Abeer H, Peter L, Hildegard SL. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur J Pharm Sci 2001;12:405-15.
27. Manthena VSV, Ramesh P. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 2005a;25:445-53.
28. Marival B, Alex A, Ana R, et al. PAMPA - a drug absorption in vitro model: 7. Comparing rat in situ, Caco-2 and PAMPA permeability of fluoroquinolones. Eur J Pharm Sci 2004; 21:429-41.
29. Chayapathy I, Piyush G, Arvind KB. Implications of density correction in gravimetric method for water flux determination using rat single-pass intestinal perfusion technique: a technical note. AAPS PharmSciTech 2003;4:44-9.
30. Isleyen EAO, Ozden T, Ozilhan S, Toptan S. Quantitative determination of fexofenadine in human plasma by HPLC-MS. Chromatographia Suppl 2007;66:109-13.
31. Zerrouk N, Chemtob C, Arnaud P, et al. In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions. Int J Pharm 2001;225:49-62.
32. Paulo C. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-33.
33. Mukne AP, Nagarsenker MS. Triamterene-b-cyclodextrin systems: preparation, characterization and in vivo evaluation. AAPS PharmSciTech 2004;5:142-50.
34. Rege BD, Kao JP, Polli JE. Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 2002;16:237-46.
35. Hong-Mei P, Prabagar B, Hyun-Jong C, et al. Preparation and evaluation of fexofenadine micro emulsions for intranasal delivery. Int J Pharm 2010;395:309-16.